Raltegravir Added to Stable HAART in HIV-1 Infected Subjects With Viral Suppression and Low CD4 Recovery
Status:
Terminated
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, randomized, double blinded, placebo-controlled study designed to compare
the safety, tolerability, antiviral activity and immunological effect of raltegravir added to
a previously stable HAART regimen in the treatment of HIV-1 infected subjects with
undetectable viraemia and low CD4 recovery.
HYPOTHESIS:
Adding raltegravir to a stable HAART in patients with undetectable plasma viral load and low
CD4 recovery will result in further viral suppression and therefore higher CD4 recovery.